Johns Hopkins University

Funding Organization

Awards Grant

  • A Feasibility Assessment and a Phase I/II Trial of MLN518 for Treatment of Patients with Recurrent Glioblastoma
  • A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)
  • A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM
  • A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide
  • A Phase I/II Trial of Hydroxychloroquine in Conjunction with Radiation Therapy and Concurrent and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (Therapeutics Studies of Anaplastic Glioma)
  • A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma
  • A Pragmatic Trial to Evaluate the Intermediate-Term Effects of Early, Aggressive Versus Escalation Therapy in People with Multiple Sclerosis (Traditional versus Early Agressive Therapy for Multiple Sclerosis (TREAT-MS) Trial
  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953
  • A Prospective Cohort Study of Cryptococcus
  • A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)
  • A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination with Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), In Patients with Her2-Positive Metastatic Breast Cancer who have Progressed on Prior Trastuzumab and Pertuzumab: The "AVIATOR” Study
  • Adult Brain Tumor Consortium
  • An Open Label, Phase 2 Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients with Recurrent Glioblastoma Mutiforme
  • COMPLETED - SPORE in Cervical Cancer - Project 3
  • COMPLETED - SPORE in Cervical Cancer - Project 4
  • COMPLETED - SPORE in Cervical Cancer - Project 5
  • Caregiving and Health Care Utilization After Stroke Among Medicare Beneficiaries
  • Center on Health Services Training and Research (CoHSTAR) New Part Time, Faculty Fellowship
  • Clot Lysis: Evaluating Acceletrated Resolution of IVH Phase III (The CLEAR III Trial)
  • Exercise and Body Composition in Juvenile Idiopathic Arthritis
  • Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media
  • FIXIT Task Order METRC - Major Extremity Trauma Research Consortium - A Prospective Randomized Trial to Assess Fixation Strategies for Severe Open Tibia Fractures: Modern Ring External Fixators vs. Internal Fixation (FIXIT Study)
  • Feasibility and Preliminary Effectiveness of a Transdiagnostic Cognitive Behavioral Therapy Treatment Approach for Alcohol Misuse Integrated Within HIV Care in Zambia
  • Genetic Modifiers of Cystic Fibrosis
  • HIV Training Through Prevention Training Centers
  • HOPE in Action: A Clinical Trial of HIV-to-HIV Deceased Donor Kidney Transplantation
  • HPV E5 as a Target for Therapeutics to Treat Precancerous and Benign HPV Lesions
  • Heart Failure with Preserved EF: Female sex-hormones and cycle GMP-PKG Modula
  • Hirschsprung Disease Research Collaborative (HDRC)
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
  • Hydroxyurea to Prevent CNS Complications of Sickle Cell Disease in Children
  • IMPAACT 1077BF, PROMISE
  • IMPAACT P1115
  • IMPAACT Protocol P1070 Co-Chair
  • International Maternal Medicine Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership (P1066)
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1093)
  • International Maternal Pediatric Adolescent AIDS Clinical Trails (IMPAACT) Group Leadership (P1110)
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group (P1097 and P1101)
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group - P1097A LAB 05
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group Leadership
  • METRC - Major Extremity Trauma Research Consortium
  • METRC - Major Extremity Trauma Research Consortium - Administrative Core
  • MISTIE lll: A Phase lll, Randomized, Open-label, 500-subject Clinical Trial of Minimally Invasive Surgery Plus rt-PA in the Treatment of Intracerebral Hemorrhage
  • Making PROMISE Meaningful to Patients and Providers in Clinical Practice
  • Mechanisms of Neurodegeneration and Strategies for Neuroprotection in MS
  • Mechanistic Analyses of a Novel RNA Polymerase I Transcription Checkpoint.
  • Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD
  • Multicenter Genetic Epigenetic & Expression Analysis of DCIS Outcome Predictors
  • N0874: Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
  • Neurofibromatosis Type 1 Dermal Neurofibroma Longitudinal Natural History Study and Selumetinib Clinical Trial
  • Neuromuscular Strain in Chronic Fatigue Syndrome (CFS)
  • North Amererican AIDS Cohort Collaboration on Research Design
  • North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD) Johns Hopkins Subcontract
  • North American AIDS Cohorts on Collaboration and Design (NAACCORD)
  • OUTLET Task Order METRC - Major Extremity Trauma Research Consortium - Outcomes Following Severe Distal Tibia, Ankle and/or Foot Trauma: Comparison of Limb Salvage vs. Transtibial Amputation Protocol (OUTLET Study)
  • POVIV Task Order METRC - Major Extremity Trauma Research Consortium - A Prospective Randomized Trial to Assess PO versus IV Antibiotics for the Treatment of Early Post-op Wound Infection after Extremity Fractures (POvIV)
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)
  • Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma
  • Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
  • Phase I/II Study of the Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients with Newly Diagnosed Malignant Glioma
  • Phase I/II Trial of Temozolomide and ABT-888 in Subjects with Newly Diagnosed
  • Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma
  • Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients
  • Prospective Cohort Study of Cryptococcus
  • Prospective Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients
  • SPORE in Cervical Cancer
  • SPORE in Cervical Cancer
  • SPORE in Cervical Cancer
  • SPORE in Cervical Cancer - Administrative Core
  • SPORE in Cervical Cancer - Administrative Core
  • SPORE in Cervical Cancer - Biostatistics Core
  • SPORE in Cervical Cancer - Cervical SPORE Pilot Project (Charles Leath)
  • SPORE in Cervical Cancer - Core B (Biostatical)
  • SPORE in Cervical Cancer - Core C (Tissue)
  • SPORE in Cervical Cancer - Core D (Career Development)
  • SPORE in Cervical Cancer - Creating a Cervical Cancer Cell Line Genomics Encyclopedia
  • SPORE in Cervical Cancer - Developmental Research Program
  • SPORE in Cervical Cancer - Pilot Project: An Assessment of Immunogenicity in Adolescent Women receiving Gardasil, Gardasil 9, or Cervarix
  • SPORE in Cervical Cancer - Pilot Project: T-cell Mediated Immunity in TC-1 Tumor Bearing Mice Treated by Sequential Radiation and Therapeutic ANAX5-E7 Protein
  • SPORE in Cervical Cancer - Project 1
  • SPORE in Cervical Cancer - Project 1
  • SPORE in Cervical Cancer - Project 2
  • SPORE in Cervical Cancer - Project 2
  • SPORE in Cervical Cancer - Project 3
  • SPORE in Cervical Cancer - Project 4
  • SPORE in Cervical Cancer - Project 5
  • SPORE in Cervical Cancer - Tissue Core
  • SPORE in Cervical Cancer - Tissue Core
  • STREAM Task Order METRC - Major Extremity Trauma Research Consortium - Streamlining Trauma Research Evaluation with Advanced Measurement (STREAM Study)
  • Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)
  • TBCRC 029_Clinical and Biological Characterization of Male Breast Cancer
  • TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)
  • TBCRC 040: Pathologic Response Evaluation & Detection In Circulating Tumor DNA (PREDiCT DNA)
  • TBCRC 048 UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes
  • TBCRC 049 UAB 1794: A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
  • TBCRC017: The Correlation of Radiographic Complete Response on Breast MRI with Pathologic Complete Response in Patients Receiving Neoadjuvant Systemic Treatment
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
  • TBCRC034: The Incidence of Adjacent Synchronous lpsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with lntraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle Biopsy
  • The Association of Allergic Disease with Clinical Outcomes in COPD
  • The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide
  • Transitions to Family Caregiving and Its Impact on Health Indicators
  • UAB 1017/TBCRC 008: A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and nab-Paclitaxel (CP)With or Without Vorinostat as Preoperative Chemotherapy in HER-2 Negative Primary Operable Breast Cancer
  • UAB 1017/TBCRC 008:A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrogate Biomarkers to Carboplatin and Nab-Paclitaxel (CP) With or Without Vorinostat as Preoperative Chemotherapy in Her2-Negative Primary Operable Breast Cancer
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study
  • UAB 1019/TBCRC 015: Investigation of Genetic Determinants of Capecitabine Toxicity
  • UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis
  • UAB 1052-TBCR020: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Lobular Neoplasia of the Breast by Core Needle Biopsy
  • UAB 1527 – A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer
  • VANCO Task Order METRC - Major Extremity Trauma Research Consortium - Local Antibiotic Therapy to Reduce Infection after Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression